TRIM21

TRIM21 Full Name

tripartite motif containing 21

TRIM21 Introduction

TRIM21 (tripartite motif containing 21), also widely known as Ro52, has emerged as a highly important immune-regulatory target in modern molecular medicine. Researchers studying autoimmune disorders, antiviral immunity, and inflammatory signaling increasingly focus on TRIM21 because it acts as both an intracellular antibody receptor and an E3 ubiquitin ligase that helps maintain immune balance. Structurally, TRIM21 contains a RING domain, B-box motifs, a coiled-coil region, and a PRY/SPRY domain that recognizes antibody-coated pathogens inside cells. This unique mechanism allows TRIM21 to identify viruses that escape extracellular immune defenses and target them for rapid proteasomal degradation. Beyond antiviral protection, TRIM21 also participates in protein quality control and cellular stress responses by regulating the degradation of misfolded or excess proteins, making it highly relevant for scientists investigating chronic inflammation, neurodegeneration, and immune dysregulation.

One of the major reasons TRIM21 attracts clinical attention is its strong association with autoimmune diseases, particularly systemic lupus erythematosus (SLE) and primary Sjögren's syndrome. Many patients with these disorders develop anti-Ro52 autoantibodies, which are widely used in diagnostic testing and disease monitoring. Recent studies suggest that abnormal TRIM21 expression can disrupt interferon signaling, IL-23/Th17 immune pathways, and cytokine homeostasis, contributing to persistent inflammation and tissue damage. TRIM21 also functions as a negative regulator of excessive innate immune activation by promoting the ubiquitination and degradation of signaling molecules such as IRF3, IRF7, and STING. This protective mechanism is especially important because uncontrolled type I interferon responses are strongly linked to lupus progression and systemic autoimmunity. Reduced TRIM21 expression observed in lupus patient immune cells has further strengthened interest in the TRIM21-STING axis as a potential therapeutic strategy for controlling chronic autoimmune inflammation without completely suppressing host immunity.

In cancer biology and translational medicine, TRIM21 demonstrates complex and context-dependent behavior that continues to drive intensive research. Depending on tumor type and cellular background, TRIM21 may function either as a tumor suppressor or as a promoter of cancer progression. Recent evidence indicates that TRIM21 regulates receptor tyrosine kinase stability, including PDGFRβ, through ubiquitin-mediated protein turnover, influencing cell proliferation and signaling homeostasis. Investigators are also exploring how TRIM21 affects tumor metabolism, interferon responses, and immune escape pathways, particularly in glioblastoma, lymphoma, and breast cancer research. In addition, its role in clearing abnormal protein aggregates has generated growing interest in neurodegenerative diseases such as Alzheimer's disease. Because TRIM21 sits at the intersection of innate immunity, intracellular pathogen defense, ubiquitin signaling, and inflammatory regulation, it is increasingly viewed as a promising biomarker and therapeutic target for autoimmune diseases, viral infections, cancer, and immune-mediated disorders.

Alternate Names for TRIM21

52 kDa ribonucleoprotein autoantigen Ro/SS-A; 52 kDa Ro protein; 52kD Ro/SSA autoantigen; Autoantigen Ro/SSA, 52-KD; E3 ubiquitin-protein ligase TRIM21; RING finger protein 81; RNF81; Ro 52; Ro(SS-A); Ro52; RO52_HUMAN; Sicca syndrome antigen A; Sjoegren syndrome type A antigen; Sjogren syndrome antigen A1; Sjogren syndrome type A antigen; SS-A; SSA; SSA1: Sjogren syndrome antigen A1 (52kDa ribonucleoprotein autoantigen SS-A/Ro); TRIM21; Tripartite motif protein TRIM21; Tripartite motif-containing 21; Tripartite motif-containing protein 21;

• 1.Jones EL, et al.; TRIM21/Ro52 - Roles in Innate Immunity and Autoimmune Disease. Front Immunol. 2021, 12:738473.
  2.Hsu CH, Yu YL. The interconnected roles of TRIM21/Ro52 in systemic lupus erythematosus, primary Sjögren's syndrome, cancers, and cancer metabolism. Cancer Cell Int. 2023, 23(1):289.